ResMed Inc. $RMD Shares Sold by Sumitomo Mitsui Trust Group Inc.

Posted by Francis Steltz on Nov 4th, 2026

Sumitomo Mitsui Trust Group Inc. reduced its stake in shares of ResMed Inc. (NYSE:RMD – Free Report) by 3.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 336,487 shares of the medical equipment provider’s stock after selling 11,350 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.24% of ResMed worth $74,397,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in ResMed during the 3rd quarter worth approximately $7,916,000. Moss Adams Wealth Advisors LLC lifted its holdings in shares of ResMed by 3.1% in the third quarter. Moss Adams Wealth Advisors LLC now owns 3,477 shares of the medical equipment provider’s stock valued at $769,000 after purchasing an additional 103 shares in the last quarter. MGO One Seven LLC bought a new position in shares of ResMed in the third quarter valued at approximately $300,000. United Asset Strategies Inc. boosted its position in shares of ResMed by 1.9% during the third quarter. United Asset Strategies Inc. now owns 16,934 shares of the medical equipment provider’s stock valued at $3,744,000 after buying an additional 318 shares during the last quarter. Finally, Choreo LLC boosted its position in shares of ResMed by 9.7% during the third quarter. Choreo LLC now owns 4,297 shares of the medical equipment provider’s stock valued at $950,000 after buying an additional 381 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Royal Bank Of Canada boosted their target price on ResMed from $262.00 to $288.00 and gave the stock an “outperform” rating in a research note on Friday, October 30th. Jefferies Financial Group lowered their target price on ResMed from $240.00 to $225.00 and set a “hold” rating on the stock in a research note on Friday, July 10th. Robert W. Baird set a $213.00 price target on shares of ResMed in a report on Friday, August 7th. Citigroup increased their price target on shares of ResMed from $240.00 to $270.00 and gave the company a “neutral” rating in a research report on Friday, October 30th. Finally, Rothschild & Co Redburn assumed coverage on shares of ResMed in a report on Wednesday, August 19th. They set a “neutral” rating and a $230.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $253.69.

Read Our Latest Analysis on ResMed

Insider Activity at ResMed

In related news, General Counsel Michael J. Rider sold 400 shares of the stock in a transaction on Friday, October 23rd. The stock was sold at an average price of $255.00, for a total value of $102,000.00. Following the completion of the transaction, the general counsel owned 12,318 shares in the company, valued at $3,141,090. This trade represents a 3.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael J. Farrell sold 4,991 shares of the stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $226.33, for a total transaction of $1,129,613.03. Following the completion of the sale, the chief executive officer directly owned 479,803 shares of the company’s stock, valued at $108,593,812.99. This trade represents a 1.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 16,343 shares of company stock valued at $3,596,098. Corporate insiders own 0.58% of the company’s stock.

ResMed News Roundup

Here are the key news stories impacting ResMed this week:

Positive Sentiment: ResMed’s earnings-call outlook pointed to continued growth despite headwinds related to its Astral products. Separately, UBS said the company is likely to sustain earnings growth. ResMed Earnings Call Signals Growth Despite Astral Headwinds ResMed Likely Able to Sustain Earnings Growth, UBS Says
Positive Sentiment: A report on the quarter highlighted 7% core constant-currency revenue growth and noted that patients taking GLP-1 drugs are more likely to start CPAP therapy—potentially supporting demand over time. ResMed: 3 Key Takeaways for Long-Term Investors
Positive Sentiment: Several analyst price targets were raised, including targets of $250, $270 and $277, signaling potential upside in those analysts’ views. ResMed Price Target Raised to $277 ResMed Price Target Raised to $270 ResMed Price Target Raised to $250
Neutral Sentiment: ResMed reported 559.448 million ASX-listed CHESS Depositary Interests for October. The update concerns its Australian-listed securities and, by itself, does not indicate a change in business performance. ResMed Reports October Decline in ASX CDIs
Negative Sentiment: Canaccord Genuity cut its rating on ResMed from Buy to Hold, removing a source of bullish analyst support. A separate Seeking Alpha assessment argued the company is high quality but not yet a bargain, highlighting valuation as a potential constraint. Canaccord Genuity Group ratings ResMed: A Quality Compounder, But Not Yet A Bargain

ResMed Stock Down 2.7%

Shares of NYSE:RMD opened at $226.56 on Wednesday. ResMed Inc. has a 1-year low of $180.26 and a 1-year high of $277.67. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.65 and a quick ratio of 1.88. The stock has a market cap of $31.87 billion, a P/E ratio of 20.20, a P/E/G ratio of 1.43 and a beta of 0.77. The firm has a fifty day moving average price of $231.77 and a 200 day moving average price of $225.16.

ResMed (NYSE:RMD – Get Free Report) last announced its earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.67 by $0.24. The business had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.39 billion. ResMed had a net margin of 27.79% and a return on equity of 26.42%. The business’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.55 earnings per share. Sell-side analysts predict that ResMed Inc. will post 12.14 EPS for the current year.

ResMed Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Investors of record on Thursday, November 12th will be paid a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Thursday, November 12th. ResMed’s dividend payout ratio (DPR) is 24.04%.

ResMed Profile

(Free Report)

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.